ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share in line with the Zacks Consensus Estimate. This compares to a loss of$0.2 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.12 per share when it actually produced a loss of$0.15, delivering a surprise of -25%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.ImmunityBio, which belongs to the ...